FilingReader Intelligence
Rohto Pharmaceutical raises full-year profit forecast on dividend income
August 6, 2025 at 12:02 PM UTC•By FilingReader AI
Rohto Pharmaceutical revised its full-year consolidated earnings forecast upward, with ordinary income now expected at 43bn yen and profit attributable to owners at 31.5bn yen.
First-quarter sales rose 19.9% year-on-year to 81.96bn yen, driven by strong performance in Asia and Europe. The forecast revisions reflect dividend income recorded in the first quarter.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
Notice regarding revisions to earnings forecastsAugust 6, 2025 at 06:30 AM UTC
Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2026August 6, 2025 at 06:30 AM UTC
Results of Operations for Q1 2025 (AprilーJune)August 6, 2025 at 06:30 AM UTC
Consolidated financial results for the first quarter of the fiscal year ending March 2026 [Japanese GAAP]August 6, 2025 at 06:30 AM UTC
First quarter earnings presentation for the fiscal year ending March 2026 (April to June 2025)August 6, 2025 at 06:30 AM UTC
TSE:4527•Tokyo Stock Exchange
News Alerts
Get instant email alerts when Rohto Pharmaceutical publishes news
Free account required • Unsubscribe anytime